Quarterly ResultMay 12, 2026, 04:08 PM
Vyome Holdings Q1 Revenue $31.6K, Net Loss $985.5K; Cash $8.8M
AI Summary
Vyome Holdings, Inc. reported a significant decrease in revenue and an increased net loss for the first quarter ended March 31, 2026. Revenue fell to $31,591 from $198,581 year-over-year, while net loss widened to $985,521 from $293,974. Despite the losses, the company's cash and cash equivalents increased to $8.8 million, largely due to $5.3 million from an At-The-Market (ATM) financing facility. Vyome continues to advance its clinical pipeline, with its lead program VT-1953 planning FDA discussions in Q2 2026 and VB-1953 being Phase III ready.
Key Highlights
- Q1 2026 revenue decreased to $31,591 from $198,581 in Q1 2025.
- Net loss for Q1 2026 widened to $985,521 from $293,974 in Q1 2025.
- Cash and cash equivalents increased to $8,795,783 as of March 31, 2026.
- Proceeds from ATM financing totaled $5,288,868 during the quarter.
- Research and development expenses rose to $666,405 in Q1 2026 from $90,268 in Q1 2025.
- Operating loss for Q1 2026 was $(1,129,940), compared to $(198,998) in Q1 2025.
- Lead program VT-1953 plans FDA discussions for pivotal trial in Q2 2026.
- VB-1953 program for inflammatory acne is Phase III ready after positive Phase II results.